Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on a 5 Component Acellular Pertussis Vaccine in Infants and Toddlers

Trial Profile

Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on a 5 Component Acellular Pertussis Vaccine in Infants and Toddlers

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2014

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary) ; DTaP poliovirus vaccine; DTaP vaccine; Hib vaccine conjugate; Poliovirus vaccine inactivated
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 31 May 2012 Status changed from active, no longer recruiting to completed.
    • 24 Sep 2008 Planned end date identified as Apr 2009, as reported by ClinicalTrials.gov.
    • 04 May 2008 Primary endpoint 'seroconversion rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top